![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Population Pharmacokinetic Analysis of Ledipasvir
(GS-5885) in Healthy and Hepatitis C Virus-Infected Subjects
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 19-21, 2014, Washington, DC
Brian Kirby,1 Hanbin Li,2 Brian P. Kearney,1 and Anita Mathias1
1Gilead Sciences, Inc., Foster City, California; 2Quantitative Solutions, Inc., Menlo Park, California
![Pharm1.gif](../images/052514/052514-3/Pharm1.gif)
![Pharm2.gif](../images/052514/052514-3/Pharm2.gif)
![Pharm3.gif](../images/052514/052514-3/Pharm3.gif)
![Pharm4.gif](../images/052514/052514-3/Pharm4.gif)
![Pharm5.gif](../images/052514/052514-3/Pharm5.gif)
![Pharm6.gif](../images/052514/052514-3/Pharm6.gif)
![Pharm7.gif](../images/052514/052514-3/Pharm7.gif)
![Pharm8.gif](../images/052514/052514-3/Pharm8.gif)
![Pharm9.gif](../images/052514/052514-3/Pharm9.gif)
![Pharm10.gif](../images/052514/052514-3/Pharm10.gif)
![Pharm11.gif](../images/052514/052514-3/Pharm11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|